Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan plus sildenafil versus sildenafil monotherapy in symptomatic pulmonary arterial hypertension
2005-005068-97Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Sildenafil monotherapy with Bosentan plus sildenafil (2 arms). Primary endpoint: Time to first adjudicated morbidity/mortality event. Started Feb 2006; status: completed.
02
Drugs
bosentansildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2005-005068-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005068-97.